Cancers | Free Full-Text | HDAC Inhibitors in Acute Myeloid Leukemia
A Randomized Comparison of Modified Intermediate-dose Ara-C versus High-dose Ara-C in Post-remission Therapy for Acute Myeloid Leukemia | Anticancer Research
Structural insights into HDAC6 tubulin deacetylation and its selective inhibition | Nature Chemical Biology
RGFP966 Datasheet
HDAC deacethylation mechanism in leukemic cells . Overexpression of... | Download Scientific Diagram
Inhibition of Histone Deacetylases 1 and 6 Enhances Cytarabine-Induced Apoptosis in Pediatric Acute Myeloid Leukemia Cells | PLOS ONE
IN ACUTE MYELOID LEUKEMIA, THE USE IN INDUCTION OF STANDARD DOSE ARA-C IS ASSOCIATED WITH A BETTER QUALITY OF RESPONSE AS COMPARED TO AN INDUCTION REGIMEN. - ppt download
Panobinostat Enhances Cytarabine and Daunorubicin Sensitivities in AML Cells through Suppressing the Expression of BRCA1, CHK1, and Rad51 | PLOS ONE
Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia | Blood Cancer Journal
2'-Fluoro-2'-deoxy-ara-C(Bz)-3'-phosphoramidite | Cytidine Analog | MedChemExpress
Expression profiles of classes I, II, and IV HDACs and sensitivities to... | Download Scientific Diagram
AML consolidation therapy: timing matters | Journal of Cancer Research and Clinical Oncology
Valproic acid enhances the antileukemic effect of cytarabine by triggering cell apoptosis
Molecular Targeting and Rational Chemotherapy in Acute Myeloid Leukemia. - Abstract - Europe PMC
Targeting HDAC3, a new partner protein of AKT in the reversal of chemoresistance in acute myeloid leukemia via DNA damage response | Leukemia
Molecules | Free Full-Text | Natural Compound Histone Deacetylase Inhibitors (HDACi): Synergy with Inflammatory Signaling Pathway Modulators and Clinical Applications in Cancer
A Randomized Comparison of Modified Intermediate-dose Ara-C versus High-dose Ara-C in Post-remission Therapy for Acute Myeloid Leukemia | Anticancer Research
Ribonucleotide reductase inhibitors suppress SAMHD1 ara‐CTPase activity enhancing cytarabine efficacy | EMBO Molecular Medicine
![PDF] Panobinostat Enhances Cytarabine and Daunorubicin Sensitivities in AML Cells through Suppressing the Expression of BRCA1, CHK1, and Rad51 | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/f668094fba2a13c35b48a8e49e9586d85158d88a/11-Figure6-1.png "PDF] Panobinostat Enhances Cytarabine and Daunorubicin Sensitivities in AML Cells through Suppressing the Expression of BRCA1, CHK1, and Rad51 | Semantic Scholar")
PDF] Panobinostat Enhances Cytarabine and Daunorubicin Sensitivities in AML Cells through Suppressing the Expression of BRCA1, CHK1, and Rad51 | Semantic Scholar
Romidepsin enhances the efficacy of cytarabine in vivo, revealing histone deacetylase inhibition as a promising therapeutic strategy for KMT2A-rearranged infant acute lymphoblastic leukemia | Haematologica
Conserved in vitro expression of HDAC repressors and modulators of ARAC... | Download Scientific Diagram
Clofarabine for the treatment of adult acute myeloid leukemia | Future Oncology
Biomedicines | Free Full-Text | Understanding Failure and Improving Treatment Using HDAC Inhibitors for Prostate Cancer
